CD274 and gastric cancer: Notably, the anti-PD-1 antibody nivolumab (Opdivo®) is approved in Japan as third-line treatment for gastric cancer and the anti-PD-1 antibody pembrolizumab (Keytruda®) recently received FDA approval for the treatment of patients with PD-L1 positive gastric and gastroesophageal junction adenocarcinoma.